Boulder BrandsBoulder Brands ( BDBD) is a marketer of functional food products under the Smart Balance, Earth Balance and Bestlife trademarks. This stock closed up 2.5% to $9.85 on Tuesday. Tuesday's Range: $9.60-$9.95 52-Week Range: $5.56-$13.99 Volume: 469,000 Three-Month Average Volume: 1.04 million From a technical perspective, BDBD bounced modestly higher here right off some near-term support at $9.50 with lighter-than-average volume. This stock has been uptrending for the last month and change, with shares pushing higher from its low of $8.16 to its recent high of $9.99. During that move, shares of BDBD have been mostly making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of BDBD within range of triggering a major breakout trade. That trade will hit BDBD manages to take out some near-term overhead resistance levels at $9.80 to $9.99 with high volume. Traders should now look for long-biased trades in BDBD as long as it's trending above some key near-term support at $9.50 or above its 50-day at $9.02 and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.04 million shares. If that breakout hits soon, then BDBD will set up to re-test or possibly take out its next major overhead resistance levels at its 200-day moving average of $11.29 to $12, or even $13. MEI PharmaMEI Pharma ( MEIP) is developing cancer therapeutics based on the central design of naturally occurring compounds called isoflavones. This stock closed up 3.5% to $9.24 on Tuesday. Tuesday's Range: $8.87-$9.30 52-Week Range: $1.98-$13.20 Volume: 56,000 Three-Month Average Volume: 94,413 From a technical perspective, MEIP bounced higher here right above its 50-day moving average of $8.46 with lighter-than-average volume. This stock has been trending sideways in a tight consolidation pattern for the last two months, with shares moving between $7.29 on the downside and $9.65 on the upside. Shares of MEIP are now finding support at its 50-day and it's quickly moving within range of triggering a major breakout. That breakout will hit if MEIP manages to take out some key near-term overhead resistance levels at $9.50 to $9.65 with high volume.
Sunshine Heart (SSH) plunges after the company, known for its C-Pulse Heart Assist System to treat moderate to severe heart failure, reported a fourth-quarter loss per share that was wider than analysts' expectations and also provided a discouraging update on a pivotal trial. The company noted a loss of 42 cents a share, wider than the consensus estimate of 40 cents a share. Sunshine Heart reported no revenue, as expected. Sunshine Heart also provided an update on its pivotal C-Pulse® COUNTER HF U.S. investigational study and noted the activation of eight sites with a total of 24 additional sites committed to participate, which increases the total number to 32. The company reported in January 2014 that one additional patient had enrolled in the trial for a total of three patients through year-end. Unfortunately, the pace of enrollment in the trials has been extremely slow. The trial, which would have an estimated enrollment of 388, began in Nov. 2012 and has an estimated data collection date of April 2016 and an estimated study completion date of April 2017.